Logotype for Capricor Therapeutics Inc

Capricor Therapeutics (CAPR) FDA announcement summary

Event summary combining transcript, slides, and related documents.

Logotype for Capricor Therapeutics Inc

FDA announcement summary

21 Nov, 2026

Introduction and purpose

  • Regulatory update on the resubmitted Deramiocel BLA for Duchenne muscular dystrophy (DMD).

Details of approval or decision

  • FDA issued a Complete Response Letter (CRL), finding the data insufficient to establish substantial evidence of effectiveness and citing other clinical deficiencies.

Impact on industry and stakeholders

  • The CRL prompted an expression of disappointment for people living with DMD and their families.

  • As of Sept. 30, 2026, cash, cash equivalents, restricted cash and marketable securities totaled ~$198.5 million, believed sufficient for at least 12 months of planned operations.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Capricor Therapeutics